Spots Global Cancer Trial Database for recurrent ovarian cancer
Every month we try and update this database with for recurrent ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | NCT04457089 | Recurrent Ovari... Platinum-sensit... | Simvastatin 40m... | 18 Years - | Cedars-Sinai Medical Center | |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer | NCT03632798 | Recurrent Ovari... | ChemoID assay Chemotherapy | 18 Years - | Cordgenics, LLC | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | NCT06308406 | Recurrent Ovari... | Bevacizumab； HR... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | NCT04201561 | Chemotherapy-in... Recurrent Ovari... Ovarian Cancer Fallopian Tube ... Primary Periton... | sodium selenite... Normal saline Chemotherapy | 19 Years - 80 Years | Seoul National University Hospital | |
| Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | NCT03025867 | Recurrent Ovari... | Niraparib | 18 Years - | Tesaro, Inc. | |
| Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer | NCT03618706 | Recurrent Ovari... | Involved-field ... | 19 Years - | Yonsei University | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers | NCT01659554 | Recurrent Ovari... Fallopian Tube ... | Cisplatin Doxorubicin | 18 Years - | Columbia University | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT05942300 | Recurrent Ovari... | CPI-0209 carboplatin | 18 Years - | University of Pittsburgh | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | NCT00477386 | Ovarian Cancer | decitabine | 18 Years - | Indiana University | |
| An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer | NCT01869400 | Recurrent Ovari... | 18 Years - | PharmaMar, Spain | ||
| Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT04729608 | Platinum-resist... | Batiraxcept Paclitaxel Placebo | 18 Years - | Aravive, Inc. | |
| Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | NCT05270720 | Recurrent Ovari... | dendritic cell | 18 Years - 75 Years | West China Second University Hospital | |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | NCT01824615 | Ovarian Cancer Adverse Effects | Sunitinib | 20 Years - 80 Years | Cathay General Hospital | |
| Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients | NCT06070285 | Recurrent Ovari... | 18 Years - | Power Life Sciences Inc. | ||
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | NCT03430518 | HER2-Negative M... Recurrent Ovari... | Durvalumab Eribulin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer | NCT01639885 | Recurrent Ovari... | Interferon Alfa... Interferon Alfa... p53 SLP | 18 Years - | Leiden University Medical Center | |
| A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer | NCT01851746 | Recurrent Ovari... | 18 Years - 70 Years | Wuhan University | ||
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT01381861 | Recurrent Ovari... Fallopian Tube ... Primary Periton... | Carotuximab (TR... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer | NCT01851746 | Recurrent Ovari... | 18 Years - 70 Years | Wuhan University | ||
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | NCT02083536 | Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari... | Low Dose Fracti... Docetaxel | 18 Years - 80 Years | University of Miami | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer | NCT01639885 | Recurrent Ovari... | Interferon Alfa... Interferon Alfa... p53 SLP | 18 Years - | Leiden University Medical Center | |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | NCT01824615 | Ovarian Cancer Adverse Effects | Sunitinib | 20 Years - 80 Years | Cathay General Hospital | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| Signal TrAnsduction Pathway Activity Analysis in OVarian cancER | NCT03458221 | Recurrent Ovari... Signal Transduc... Therapy-Associa... | Letrozole Oral ... Bicalutamide Or... Everolimus Oral... Itraconazole Or... | 18 Years - | Gynaecologisch Oncologisch Centrum Zuid | |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | NCT02083536 | Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari... | Low Dose Fracti... Docetaxel | 18 Years - 80 Years | University of Miami | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | NCT05211557 | Ovarian Cancer | fhB7H3.CAR-Ts | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | NCT05311579 | Ovarian Carcino... Survival Outcom... Adverse Events Niraparib Anlotinib CA125 Chemotherapy Targeted Therap... Recurrent Ovari... | Niraparib plus ... | 18 Years - | Peking Union Medical College Hospital | |
| Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | NCT02035345 | Recurrent Ovari... Platinum Sensit... | Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | NCT00545792 | Cervical Cancer Endometrial Can... Ovarian Cancer Vaginal Cancer Carcinoma of th... | Avastin | 18 Years - | Dana-Farber Cancer Institute | |
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | NCT03430518 | HER2-Negative M... Recurrent Ovari... | Durvalumab Eribulin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | NCT05126342 | Recurrent Ovari... Recurrent Fallo... Primary Periton... | Niraparib Dostarlimab | 18 Years - | AGO Research GmbH | |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | NCT02195973 | Recurrent Ovari... | LDE225 | 19 Years - | University of Alabama at Birmingham | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | NCT00343044 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Topotecan Bevacizumab | 18 Years - | Benaroya Research Institute | |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | NCT06365853 | Recurrent Ovari... Folate Receptor... | Mirvetuximab So... Lubricating Eye... Prednisolone ac... Brimonidine tar... | 18 Years - | ImmunoGen, Inc. | |
| Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | NCT03353831 | Recurrent Ovari... | Bevacizumab Atezolizumab Chemotherapy Placebos | 18 Years - | AGO Research GmbH | |
| Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer | NCT02303912 | Recurrent Ovari... | Nuc-1031 and Ca... | 18 Years - | Imperial College Healthcare NHS Trust | |
| Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer | NCT02849353 | Recurrent Ovari... | Cryosurgery NK immunotherap... | 30 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab | NCT05819060 | Recurrent Ovari... | Fuzuloparib Com... | 18 Years - 75 Years | Fudan University | |
| A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | NCT06308406 | Recurrent Ovari... | Bevacizumab； HR... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | NCT04091204 | BRCA Wild Type ... | Olaparib tablet... | 18 Years - | National Cancer Institute, Naples | |
| Ovarian Dendritic Cell Vaccine Trial | NCT00703105 | Ovarian Cancer | DC vaccination | 18 Years - | Loyola University | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | NCT00545792 | Cervical Cancer Endometrial Can... Ovarian Cancer Vaginal Cancer Carcinoma of th... | Avastin | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer | NCT01851746 | Recurrent Ovari... | 18 Years - 70 Years | Wuhan University | ||
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT01381861 | Recurrent Ovari... Fallopian Tube ... Primary Periton... | Carotuximab (TR... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | NCT00343044 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Topotecan Bevacizumab | 18 Years - | Benaroya Research Institute | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | NCT05170594 | Ovarian Cancer | Bevacizumab chemotherapy Fluzoparib | 18 Years - 75 Years | The Second Affiliated Hospital of Shandong First Medical University | |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | NCT04718740 | Recurrent Ovari... | fluzoparib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | NCT00055432 | Ovarian Cancer Peritoneal Canc... | Gemzar and Alim... | 18 Years - | Eli Lilly and Company | |
| Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | NCT03025867 | Recurrent Ovari... | Niraparib | 18 Years - | Tesaro, Inc. | |
| WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer | NCT01144442 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Hyperthermic in... Isotonic saline... Surgery Carboplatin Paclitaxel | 16 Years - 90 Years | Masonic Cancer Center, University of Minnesota | |
| Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | NCT04457089 | Recurrent Ovari... Platinum-sensit... | Simvastatin 40m... | 18 Years - | Cedars-Sinai Medical Center | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| H.O.P.E: Helping Ovarian Cancer Patients Cope | NCT02090582 | Platinum-resist... Recurrent Ovari... Palliative Care | Structured Pall... Usual Care | 18 Years - | Duke University | |
| MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. | NCT05255471 | Ovarian Cancer | Olaparib Chemotherapy dr... | 18 Years - | National Cancer Institute, Naples | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
